The effects of platelet receptor GPIIb/IIIa polymorphism (Leu Pro33) on the receptor expression and platelet aggregation in patients with ischaemic stroke

Turkish Journal of Hematology

Volumn 24, Issue 4, 2007, Pages 155-163

  Pongrácz, Endre ^a   Schweitzer, Katalin ^b   Fürész, József ^b   Fent, János ^b   Tordai, Attila ^c   Nagy, Zoltán ^d  

^a Central Hospital of Home Office   (Hungary)

^b Institute of Health Protection Budapest   (Hungary)

^c National Institute of Haemathology   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Arterial thrombosis; Genetic polymorphism; Genetic risk factors; GPIIb IIIa polymorphism (Leu33Pro); Ischaemic stroke; Platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; BUFFER; CD61 ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; LEUCINE; PADGEM PROTEIN; PHOSPHATE; PROLINE; RISTOCETIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; WILD TYPE;

EID: 38149122262     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hass WK, Easton DJ. Ticlopidine, platelets and vascular disease. New York: Springer Verlag, 1993.
2. Haemostasis and thrombosis In: Bloom AL, Forbes CD, Thomas DP: Tuddenham EGD eds. Churchill Livingstone, 1994.
3. Lee GR, Foerster J, Lukens J, et al. Wintrobes clinical hemathology, New York: Williams and Wilkins, 1999.
4. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrincαIIb3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992;267:11300-6.
5. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on yon Willebrand factor. Cell 1996;84:289-97.
6. Du X, Ginsberg MH. Integrin αIIbβ3 and platelet function. Thromb Haemost 1997;78:96-100.
7. Weiss EJ, Bray PU, Tayback M. A polymorphisrn of a platelet glycoprotein receptor as an inhereted risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-4.
8. Ying J, Dietz H, Nurden A, Brray FP. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993;82:2281-8.
9. Ingerman-Wojenszki C M, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood Lumi-Aggregometer. Thromb Haemost 1984;51:154-6.
10. Born GVR. Quantitative investigations into the aggregation of blood platelets. J Physiol London 1962;67:162.
11. Michelson AD. Flow cytrometry: a clinical test of platelet function. Blood 1996;87/12:4925-33.
12. McGregor JL, Brochier J, Wild F, Follea G, Trzeciak MC, James E, Dechavanne M, McGregor L, Clemetson K. Monoclonal antibodies against platelet membrane glycoproteins. Eur J Biochem 1983; 131:427-36.
13. Coller BS. Blocade of platelet GPIlb/IIIa receptors as an antihtrombotic strategy. Circulation 1995;92:2373-80.
14. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray PU. Clues to the death of an Olympic champion (Letter) Lancet 1996;347:1833-7.
15. Kekomaki S, Hamalainen L, Kauppinen-Makelin R, Palomaki H, Kaste M, Kontula K. Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischemic stroke. J Cardiovasc Risk 1999;6:13-7.
16. A1/A2 plymorphism with myocardial infarction. Am J Cardiol 2000;86:1000-5.
17. van Goor ML, Gomez GE, Bronwers GJ, Leebek FW, Koudstaal PJ. PLA1/A2 plymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Thromb Res 2002; 108:63-5.
18. Feng D, Lindpainter K, Larson MG, Rao VS, Donell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz HD, Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa P1A2 polyrmorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;8:1142-7.
19. Wagner Kathryn R, et al. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk (The stroke prevention in young woman study). Stroke 1998;29:581-5.
20. Michelson AD, Bernard MR. Thrombin induced changes in platelet membrane glycoproteins Ib, IX and IIb/IIIa complex. Blood 1987;70:1673-8.
21. Holensteiner A, Walchshofer S, Adler A, Kitti E-M, Mayr WR, Panzer S. Human platelet antigen gene frequencies in the Austrian population. Haemostasis 1995;25:133-6.
22. Marti GB, Magrude T, Schuette WE, Gralnick HR. Flow cytometric analysis of platelet surface antigens. Cytometry 1988;9:448-55.
23. Pongrácz E, Tordai A, Csornai M, Nagy Z. Stroke betegek thrombocyta glikoprotein IIb/IIIa (LeuPro33) polimorfizmusának vizsgálata. Orvosi Hetilap 2001;142:78145.
24. Goodall AH, Cruzen N, Panesar M, Hurd C, Knight CJm Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, P1A2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742-7.
25. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. J Resistance in vitro to low-dose aspirin is associated with platelet PIA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. Am Coll Cardiol 2003;42:1115-9.
26. Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis - role of HPA-lb polymorphisrn in platelet function. Blood Coagul Fibrinolysis 1997;8:284-90.
27. Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA lb (P1A2): No association with platelet fibrinogen binding. Br J Haemathol 1999;105:664-6.
28. Knight CJ, Panesar M, Wright C, Clarke D, Butowski PS, Patel D, Patrinelli A, Fpx K, Goodall AH. Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol 1997; 17:2044-53.
29. Michelson AD, Furman M, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler TH, Christie DJ, Kundu SP, Bray SP. Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:1013-8.
30. Sathiropas P, Marbet GA, Sahaphong S, Duckert E Detection of small inhibitors effects of acetilsalicylic acid (ASA) by platelet impedance aggregometry in whole blood. Thromb Res 1988;51:55-62.
31. Hézard N, Metz D, Nazeyrooas P, Droullé C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2003;108:43-7.